Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors
Public ClinicalTrials.gov record NCT02444546. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1 Study of Replication Competent Reovirus (Reolysin®) in Combination With GM-CSF in Pediatric Patients With Relapsed or Refractory Brain Tumors
Study identification
- NCT ID
- NCT02444546
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Mayo Clinic
- Other
- Enrollment
- 6 participants
Conditions and interventions
Conditions
- Childhood Astrocytoma
- Childhood Atypical Teratoid/Rhabdoid Tumor
- Diffuse Intrinsic Pontine Glioma
- Glioma
- Recurrent Childhood Anaplastic Oligodendroglioma
- Recurrent Childhood Brain Neoplasm
- Recurrent Childhood Glioblastoma
- Recurrent Childhood Medulloblastoma
- Recurrent Primitive Neuroectodermal Tumor
- Refractory Brain Neoplasm
Interventions
- Laboratory Biomarker Analysis Other
- Sargramostim Biological
- Wild-type Reovirus Biological
Other · Biological
Eligibility (public fields only)
- Age range
- 10 Years to 21 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 20, 2015
- Primary completion
- Jul 12, 2018
- Completion
- Nov 20, 2022
- Last update posted
- Apr 23, 2023
2015 – 2022
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02444546, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 23, 2023 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02444546 live on ClinicalTrials.gov.